ନୁସିନରସେନ

ନୁସିନରସେନ
Clinical data
Trade names	Spinraza
Synonyms	IONIS-SMNRx, ISIS-SMNRx
AHFS/Drugs.com	monograph
MedlinePlus	a617010
data	EU EMA: yes; US DailyMed: Nusinersen;
Pregnancy; category	AU: B1 ; US: N (Not classified yet) ; ;
Routes of; administration	Intrathecal
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Bioavailability	100% (intrathecal)
Protein binding	<25% (in CSF), >94% (in plasma)
Metabolism	Exonuclease (3’- and 5’)-mediated hydrolysis
Elimination half-life	135–177 days (in CSF), 63–87 days (in plasma)
Identifiers
	IUPAC name all-P-ambo-2’-O-(2-Methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’→5’)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’→5’)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’→5’)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-P-thioguanylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-P-thioguanylyl-(3’→5’)-2’-O-(2-methoxyethyl)guanosine;
Chemical and physical data
Formula	C234H323N61Na17O128P17S17
Molar mass	୭,୫୦୦.୮୬ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc1cn(c(=O)[nH]c1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)OP(=S)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)n4cc(c(nc4=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]5[C@H]([C@H]([C@@H](O5)n6cnc7c6ncnc7N)OCCOC)OP(=S)(O)OC[C@@H]8[C@H]([C@H]([C@@H](O8)n9cc(c(nc9=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(=O)[nH]c1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(=O)[nH]c1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(=O)[nH]c1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(nc1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cnc2c1ncnc2N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(=O)[nH]c1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cnc2c1ncnc2N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cnc2c1ncnc2N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(=O)[nH]c1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cnc2c1nc([nH]c2=O)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(nc1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(=O)[nH]c1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cnc2c1nc([nH]c2=O)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cnc2c1nc([nH]c2=O)N)OCCOC)O)OCCOC;

ନୁସିନରସେନ, ଏକ ବେପାର ନାମ ସ୍ପିନରାଜା, ହେଉଛି ମେରୁଦଣ୍ଡୀୟ ମାଂସପେଶୀ ଆଟ୍ରୋଫି (SMA)ର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ଏକ ଔଷଧ ।^[୪] ଏହା ମୋଟର କାର୍ଯ୍ୟକୁ ଉନ୍ନତ କରିଥାଏ ।^[୪] ଏହା ମେରୁଦଣ୍ଡ କେନାଲରେ ଇଞ୍ଜେକ୍ସନ ଆକାରରେ ଦିଆଯାଏ ।^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଶ୍ୱାସକ୍ରିୟା ସଂକ୍ରମଣ, କୋଷ୍ଠକାଠିନ୍ୟ ଏବଂ କାନ ସଂକ୍ରମଣ ହୋଇପାରେ ।^[୪] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ କମ ପ୍ଲାଟେଲେଟ୍, ରକ୍ତସ୍ରାବ ଏବଂ ବୃକ୍‌କ ସମସ୍ୟା ହୋଇପାରେ ।^[୪] ଗର୍ଭାବସ୍ଥାରେ ସୁରକ୍ଷା ଅସ୍ପଷ୍ଟ ଅଟେ ।^[୪] ଏହା ଏକ ଆଣ୍ଟିସେନ୍ସ ଓଲିଗୋନ୍ୟୁକ୍ଲିଓଟାଇଡ଼ ଯାହା ମୋଟୋର ନିଉରନ ବୃଦ୍ଧି କରେଇଥାଏ ।^[୫]

୨୦୧୬ ମସିହାରେ ଆମେରିକାରେ ଏବଂ ୨୦୧୭ରେ ୟୁରୋପରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ନୁସିନରସେନ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୪] ^[୬] ଯୁକ୍ତରାଜ୍ୟରେ ଏକ ମାତ୍ରାର ମୂଲ୍ୟ ୨୦୨୧ ମସିହାର ୭୫,୦୦୦ ପାଉଣ୍ଡ ଥିଲେ ।^[୫] ଯୁକ୍ତରାଷ୍ଟରେ ଏହାର ମୂଲ୍ୟ ପ୍ରାୟ ୧୩୩,୦୦୦ ଡଲାର ଅଟେ ।^[୭]

ଆଧାର

↑ ^୧.୦ ^୧.୧ "Spinraza- nusinersen injection, solution". DailyMed. 30 June 2020. Archived from the original on 17 October 2020. Retrieved 3 November 2020.
↑ Paton, D.M. (2017). "Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy". Drugs of Today. Clarivate Analytics (US). 53 (6): 327–337. doi:10.1358/dot.2017.53.6.2652413. ISSN 1699-3993. PMID 28799578.
↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 74" (PDF). World Health Organization. pp. 413–414. Archived (PDF) from the original on 18 May 2016. Retrieved 13 March 2017.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ "Nusinersen Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 21 January 2021. Retrieved 13 November 2021.
↑ ^୫.୦ ^୫.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1170. ISBN 978-0857114105.
↑ "Spinraza". Archived from the original on 4 January 2021. Retrieved 13 November 2021.
↑ "Spinraza Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 10 September 2021. Retrieved 13 November 2021.

[Spinraza_FDA_label-1] ୧.୦ ^୧.୧ "Spinraza- nusinersen injection, solution". DailyMed. 30 June 2020. Archived from the original on 17 October 2020. Retrieved 3 November 2020.

[Paton_2017_p=327-2] Paton, D.M. (2017). "Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy". Drugs of Today. Clarivate Analytics (US). 53 (6): 327–337. doi:10.1358/dot.2017.53.6.2652413. ISSN 1699-3993. PMID 28799578.

[INN-3] "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 74" (PDF). World Health Organization. pp. 413–414. Archived (PDF) from the original on 18 May 2016. Retrieved 13 March 2017.

[AHFS2021-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ "Nusinersen Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 21 January 2021. Retrieved 13 November 2021.

[BNF81-5] ୫.୦ ^୫.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1170. ISBN 978-0857114105.

[EPAR2021-6] "Spinraza". Archived from the original on 4 January 2021. Retrieved 13 November 2021.

[7] "Spinraza Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 10 September 2021. Retrieved 13 November 2021.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]